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 2
Abstract 24 
High consumption of simple sugars causes adverse cardio-metabolic effects. We 25 
investigated the mechanisms underlying the metabolic and vascular effects of glucose or 26 
fructose intake and determined whether these effects are exclusively related to increased 27 
calorie consumption. Female Sprague-Dawley rats were supplemented with 20% w/v 28 
glucose or fructose for 2 months, and plasma analytes and aortic response to vasodilator 29 
and vasoconstrictor agents were determined. Expression of molecules associated with 30 
lipid metabolism, insulin signalling and vascular response were evaluated in hepatic 31 
and/or aortic tissues.  Caloric intake was increased in both sugar-supplemented groups 32 
vs control, and in glucose- vs fructose-supplemented rats. Hepatic lipogenesis was 33 
induced in both groups. Plasma triglycerides were increased only in the fructose group, 34 
together with decreased expression of carnitine palmitoyltransferase-1A and increased 35 
microsomal triglyceride transfer protein expression in the liver. Plasma adiponectin and 36 
peroxisome proliferator-activated receptor (PPAR)α expression were increased only by 37 
glucose supplementation. Insulin signalling in liver and aorta were impaired in both 38 
sugar-supplemented groups, but the effect was more pronounced in the fructose group. 39 
Fructose supplementation attenuated aortic relaxation response to a nitric oxide (NO) 40 
donor, whereas glucose potentiated it. Phenylephrine-induced maximal contractions 41 
were reduced in the glucose group, which could be related to increased endothelial NO 42 
synthase (eNOS) phosphorylation and subsequent elevated basal NO in the glucose 43 
group. In conclusion, despite higher caloric intake in glucose-supplemented rats, 44 
fructose caused worse metabolic and vascular responses. This may be due to the 45 
elevated adiponectin level and the subsequent enhancement of PPARα and eNOS 46 
phosphorylation in glucose-supplemented rats. 47 
 48 
NEW & NOTEWORTHY 49 
This is the first study comparing the effects of glucose and fructose consumption on 50 
metabolic factors and aortic function in female rats. Our results show that although total 51 
caloric consumption was higher in glucose-supplemented rats, fructose ingestion had a 52 
greater impact in inducing metabolic and aortic dysfunction. 53 
 54 
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  Insulin resistance, obesity and type 2 diabetes are metabolic disturbances leading 57 
to cardiovascular diseases (CVD). CVD are main causes of morbidity and mortality in 58 
diabetes, and both micro- and macro-vascular complications are thought to play a major 59 
role in the development of CVD in pre-diabetic and diabetic patients (14, 30).  60 
  In humans, an excessive intake of added sugars has been linked to the 61 
development of metabolic disturbances (22, 39), and therefore to an increase in the risk 62 
for CVD mortality (59). Despite the evidence generated from epidemiological studies, 63 
the molecular mechanisms linking diabetes and CVD in the population with excessive 64 
sugar intake are not fully understood. At the vascular level, insulin resistance (32, 34) 65 
along with dyslipidaemia, local inflammation and a decrease in the synthesis of 66 
endothelium derived relaxation factors such as nitric oxide (NO) may play a key role in 67 
the development of CVD (25). 68 
 The adverse cardio-metabolic effects of simple sugars seem to be worse when 69 
they are ingested in liquid than in solid form, because the level of food intake is not 70 
reduced enough to compensate the extra calories provided by beverages (53), leading to 71 
an increase in total caloric intake. Consumption of simple sugars in liquid form 72 
essentially occurs as sugar-sweetened beverages (SSB), which include sodas, colas, fruit 73 
punches, lemonade, and other fruit drinks with added sugars. The main compounds used 74 
by the food industry to sweeten these beverages are high fructose corn syrup (in USA) 75 
and sucrose (in Europe), both containing approximately equal amounts of fructose and 76 
glucose (48). At present, there is an intense debate in the scientific community about 77 
whether the adverse cardiovascular and metabolic effects of SSB are mostly attributable 78 
to specific effects of the simple sugars used as sweeteners, or are merely the 79 
consequence of the increase in caloric intake and weight gain in the population 80 
consuming large quantities of SSB (10, 26, 49, 52).  81 
  To study the effects of simple sugar consumption in liquid form on glucose and 82 
lipid metabolism, the rat is a good model which has been extensively used by us (7, 41–83 
43, 54–56). In previous studies, we showed that female rats supplemented for short 84 
periods of time (14 days) with liquid fructose displayed a more detrimental response 85 
than male rats. Specifically, we reported that fructose induced hypertriglyceridemia and 86 
fatty liver in both sexes but only females showed glucose intolerance and hepatic insulin 87 
resistance (41, 56). Insulin resistance is a prominent feature of metabolic diseases such 88 
as obesity or type 2 diabetes mellitus, which is also a major risk factor for CVD. A 89 
relationship between insulin resistance and endothelial dysfunction has been proposed 90 
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as a link between cardiovascular and metabolic diseases (27).  Endothelial dysfunction 91 
is defined as a reduced endothelium-dependent vasodilation (EDV) to vasodilators, such 92 
as acetylcholine (ACh) and bradykinin (BK), or flow-mediated vasodilation. Thus, EDV 93 
is generally used as a reproducible parameter to investigate endothelial function under 94 
various pathological conditions such as diabetes, obesity and dyslipidaemia. While past 95 
studies were performed largely on males, there is increasing awareness by the NIH that 96 
research should include females. Here, we sought to study the effects of 2-month 97 
supplementation with liquid fructose or glucose (20% w/v), on the metabolic response 98 
and vascular reactivity in aorta, a large conduit artery, in female rats. To measure the 99 
vascular function, EDV was assessed by examining the aortic relaxation responses to 100 
ACh and BK (receptor-mediated NO-dependent vasodilators). Aortic response to a NO 101 
donor was also determined by measuring the relaxation responses to sodium 102 
nitroprusside (SNP). Furthermore, vasoconstrictor responses to phenylephrine (PE) 103 
were studied. Our aims were to investigate the molecular mechanisms underlying the 104 
metabolic and vascular effects of these simple sugars and to determine whether these 105 
effects are exclusively related to increased calorie consumption.   106 
 107 
Materials and methods 108 
Animals and experimental design 109 
Female Sprague-Dawley rats, aged 9–11 weeks (Simonsen Laboratories, Gilroy, 110 
CA, USA) were maintained with water and standard rodent chow food ad libitum at 111 
constant humidity and temperature, with a light/dark cycle of 12 h. After acclimation for 112 
1 week, the animals were randomly assigned to a control group, a glucose-113 
supplemented and a fructose-supplemented group (14 rats per group). Sugars were 114 
supplied as a 20 % (w/v) solution in drinking water for 8 weeks. Body weight, food and 115 
drink intake were monitored throughout the experiment. After 8 weeks, the rats were 116 
fasted for 12 h and euthanized using CO2 according to the recommendations from the 117 
2013 AVMA Guidelines on Euthanasia (28) and the NIH Guidelines for the Care and 118 
Use of Laboratory Animals: Eighth Edition (US National Institutes of Health 2011). All 119 
animal protocols were approved by the Animal Care Committee of the University of the 120 
Pacific and complied with the Guide for the Care and Use of Laboratory Animals: 121 
Eighth Edition (US National Institutes of Health 2011) and with ARRIVE guidelines. 122 
The 8-week duration of sugar supplementation was chosen in order to mimic a sub-123 
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chronic regime, as this period of ingestion in rats is roughly equivalent to 6 years of 124 
consumption in humans (45). 125 
Blood analysis  126 
Glucose, triglycerides and cholesterol were measured in 12 h fasted rats using an 127 
Accutrend® Plus System glucometer and specific test strips (Roche Farma, Barcelona, 128 
Spain) with blood collected from the tail vein. Blood samples were obtained by intra-129 
cardiac puncture and collected in tubes containing anticoagulant. Plasma was obtained 130 
by centrifugation at 10,000xg for 5 min at 4°C and stored at −80 °C until used. Leptin 131 
(Invitrogen, Camarillo, CA, USA), adiponectin (Adipogen, Liestal, Switzerland) and 132 
insulin (Spi Bio, Montigny Le Bretonneux France) levels were determined in plasma 133 
samples by ELISA kits according to the manufacturer’s protocol.  134 
Measurement of arterial tension 135 
The thoracic aortae were isolated and cleaned of fatty and adhering connective 136 
tissues and then cut into 2 mm rings, exactly. To measure isometric tension, the rings 137 
were suspended horizontally between two stainless steel hooks in individual organ baths 138 
containing 20 ml of Krebs buffer (in mM: 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 139 
MgSO4, 24.9 NaHCO3, 0.023 EDTA, 1.6 CaCl2, and 6.0 glucose) at 37°C bubbled with 140 
95% O2 and 5% CO2 (40). Isometric tension was continuously monitored with a 141 
computer based data acquisition system (PowerLab, ADInstruments, Colorado Springs, 142 
USA). The rings were equilibrated for 40 min under a resting tension of 1 g to allow 143 
development of a stable basal tone. Stimulation of rings with 80 mM KCl was repeated 144 
two times every 20 min until maximum contraction was achieved. The ability of ACh 145 
(10 μM) to induce relaxation of phenylephrine (PE, 2 μM) pre-contracted vessels was 146 
taken as an evidence for the preservation of the intact endothelium.  147 
Relaxation responses to ACh 148 
Aortic rings were contracted with PE (2 μM), a concentration that produced 80% 149 
of the maximal effect (EC80). Dilator response curves were obtained by the addition of 150 
increasing concentrations of ACh (10−8 to 10−5 M).  151 
Relaxation responses to BK 152 
The concentration response curves to BK, were measured following the addition 153 
of increasing concentrations of BK (10−9 to 10−5 M) in U46619 (100 nM) pre-contracted 154 
aortic rings taken from all groups. 155 
Relaxation responses to SNP 156 
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Responses to SNP (10−9 to 10−5 M), a NO-donor, were generated in the aortic 157 
rings pre-contracted with PE (2 μM) from all groups. 158 
Contractile responses to PE 159 
The constrictor concentration response curves to PE (10−8 to 10−5 M) were 160 
generated before and after incubation with Nω-Nitro-L-arginine methyl ester (L-NAME, 161 
200 μM), a nitric oxide synthase (NOS) inhibitor, in the presence of indomethacin 162 
(indo, 10 μM, dissolved in DMSO), a cyclooxygenase (COX) inhibitor. Between each 163 
concentration response curve, tissues were washed with Krebs buffer to allow the rings 164 
to return to the basal tone. The use of this concentration of L-NAME was based on 165 
previous studies (18, 19). A vehicle only (no drugs present) study was performed 166 
simultaneously in aortic rings from the same animal.  167 
Measurement of Nitrate and Nitrite in endothelial cells 168 
The permanently established EA.hy926 endothelial cell line (passage 5-6) 169 
(American Type Culture Collection (ATCC), Manassas, VA, USA) were plated and 170 
cultured in low glucose (1000mg/l) Dulbecco's Modiﬁed Eagle's Medium supplemented 171 
with 10% fetal bovine serum (Thermo Scientific) and antibiotics (100 U/ml penicillin 172 
and 100 μg/ml streptomycin) at 37 °C with 95% air and 5% CO2.  Upon reaching 80% 173 
confluence, cells were treated with Recombinant Human gAcrp30/Adipolean (Globular 174 
adiponectin, 5 and 15 μg/ml, Peprotech Inc., Rocky Hill, NJ, USA), glucose or fructose 175 
(25 mM, Sigma-Aldrich, St. Louis, MO, USA). The NO donor S-Nitroso-N-Acetyl-176 
D,L-Penicillamine (SNAP, 100 µM, Tocris  Biosciences, Minneapolis, MN, USA) was 177 
used as a positive control, and mannitol (25 mM, Sigma-Aldrich, St. Louis, MO, USA) 178 
as an osmotic control.  After  30 min, cell culture supernatants were collected and  NO 179 
levels were determined by measurement of the end products of its metabolism NOx 180 
[nitrate (NO3-) plus nitrite (NO2-)] using the Nitrate/Nitrite Colorimetric Assay Kit 181 
(Cayman Chemical, Ann Arbor, MI, USA) according to manufacturer’s suggestions. 182 
Five to six different samples for each condition were performed in duplicate. 183 
RNA isolation and Real-Time PCR 184 
Samples of liver, visceral white adipose and aortic tissues were weighed, 185 
immediately frozen in dry ice and stored at −80 °C until used for RNA extraction. Total 186 
RNA was isolated from liver and adipose tissue samples by using TrizolR reagent 187 
(Invitrogen™, Carlsbad, CA, USA) and from aortic samples using RNeasy mini kit 188 
(Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions. 189 
cDNA was synthesized by reverse transcription using the Omniscript reverse 190 
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transcriptase kit (Qiagen, Valencia, CA, USA). Samples were incubated at 37°C for 60 191 
min in MJ Mini™ Personal Thermal Cycler (Bio-Rad, Hércules, CA, USA). The PCR 192 
reaction was carried out in StepOnePlus™ Real-Time PCR System Thermal Cycling 193 
Block (Applied Biosystems, Foster City, CA, USA) using SYBR® Green PCR Master 194 
Mix (Applied Biosystems), 100 nM of each specific primer and 10 - 50 ng of cDNA for 195 
each gene. PCR reactions were performed in duplicate and normalized to a 196 
housekeeping gene using the 2−ΔΔCt method. The TATA box binding protein (tbp) was 197 
used as a control for liver and β-actin (actb) was used for adipose tissue and aorta. 198 
Primer sequences and PCR product length are listed in Table 1. 199 
 Preparation of total protein and nuclear extracts 200 
Aortic and visceral adipose tissue samples were micronized through freezing 201 
with liquid nitrogen and grinding with a mortar as previously described (7). Liver 202 
samples were homogenized with a Dounce homogenizer. For total protein extraction, 203 
lysis buffer with proteases, phosphatases and acetylases inhibitors (in mM: 50 Tris–HCl 204 
pH=8, 150 NaCl, 10 NaF, 1 EDTA, 1 EGTA, 2 Nappi, 1 PMSF, 1 Na3VO4, 10 NaM, 205 
0.001 TSA) plus 1% Igepal, 2 µg/mL leupeptin and 2 µg/mL aprotinin was used. 206 
Samples were incubated with this buffer for 1.5 h at 4°C, centrifuged at 15,000×g for 15 207 
min at 4°C and supernatants were collected. To obtain hepatic nuclear extracts for the 208 
determination of the transcription factors PPARα, ChREBP and SREBP-1C, 209 
homogenization buffer (in mM: 10 Tris–HCl pH=8, 1.5 MgCl2, 10 KCl, 2 Nappi, 10 210 
NaF, 0.5 DTT, 1 PMSF, 1 Na3VO4, 10 NaM, 10-6 TSA) plus 2 µg/mL leupeptin and 2 211 
µg/mL aprotinin was used. The homogenates were kept on ice for 10 min and 212 
centrifuged at 1000xg for 10 min at 4°C. Lysis buffer was added to the pellet obtained 213 
and samples were incubated for 1.5 h at 4°C, centrifuged at 25,000×g for 30 min at 4°C 214 
and supernatants were collected. Protein concentrations were determined by the 215 
Bradford method (9). 216 
Western blot analysis  217 
20-30 µg of protein was subjected to SDS-polyacrylamide gel electrophoresis. 218 
Proteins were then transferred to Immobilon polyvinylidene difluoride transfer 219 
membranes (Millipore, Billerica, MA, USA), blocked for 1 h at room temperature with 220 
5% non-fat milk solution in 0.1% Tween-20-Tris-buffered saline (TBS), and incubated 221 
overnight at 4°C with primary antibodies. Primary antibodies for p-ACC (Ser79), total 222 
ACC, p-Akt (Ser473), total Akt, p-eNOS (Ser1177), iNOS, PKG-1 (recognizing both α 223 
and βisoforms) p-VASP (Ser157), p-VASP (Ser239) and total VASP were supplied by 224 
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Cell Signaling (Danvers, MA, USA). Antibodies against IRS-1, IRS-2, ChREBP, 225 
SREBP-1c, MTP and FAS were obtained from Santa Cruz Biotechnologies (Dallas, TX, 226 
USA). PPARα, PDE4 and SCD1 antibodies were obtained from AbCam (Cambridge, 227 
UK). Antibody against rat liver CPT-1A was kindly provided by L. Herrero and D. 228 
Serra (Department of Biochemistry and Physiology, School of Pharmacy, University of 229 
Barcelona) (21, 37). Detection was performed using the Pierce® ECL Western Blotting 230 
Substrate (Thermo Scientific) and Immobilion™ Western Chemiluminescent HRP 231 
Substrate (Millipore, Billerica, MA, USA). To confirm the uniformity of protein 232 
loading, blots were incubated with β-actin or β-tubulin antibodies (Sigma-Aldrich, St. 233 
Louis, MO, USA) as a control.  234 
Data presentation and statistical analysis 235 
Results are expressed as the mean of n values ± SEM, where n represents data 236 
from one rat. Relaxation responses to ACh, BK, and SNP were calculated as the 237 
percentage of relaxation from maximum PE or U46619 contraction. Similarly, the 238 
recorded increase in the force of contraction was calculated as the percentage of 239 
maximum contraction obtained with PE at the highest dose. EC50, the concentration of 240 
the agonist which produces half of the maximum effect (Emax), was calculated by a 241 
sigmoidal dose-response model (for variable slope) using GraphPad Prism 6 (GraphPad 242 
Software Inc., San Diego, CA, USA). The sensitivity of the agonists was expressed as 243 
pD2 values (-log [EC50]). In general, statistical analyses were performed by one-way 244 
ANOVA test, after gaussian distribution of the data was verified by the Kolmogorov-245 
Smirnov normality test and equality of variance by Bartlett's test.  When the ANOVA 246 
test returned P<0.05, post-hoc analysis using Bonferroni’s test was performed. 247 
Comparison of concentration response curves between groups was done using two-way 248 
ANOVA, with one factor being concentration and the other being groups. To compare 249 
the effect of L-NAME on the PE response, the PE results were expressed as differences 250 
of area under the concentration response curve (ΔAUC) in control (absence of L-251 
NAME) and experimental (presence of L-NAME) condition. The level of statistical 252 
significance was set at P<0.05. 253 
    254 
  Results  255 
  Only fructose supplementation causes hypertriglyceridemia and increases 256 
body and liver weight 257 
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  As it is shown in Table 2, rats supplemented with 20% glucose or fructose 258 
increased their liquid consumption (by 2-fold and 1.5-fold, respectively). Further, they 259 
partially compensated the increase in caloric intake by reducing the consumption of 260 
solid food (by 0.3-fold in glucose group and by 0.5-fold in fructose group). As a result, 261 
the total amount of ingested calories was increased in both groups. However, total 262 
caloric intake in glucose-supplemented rats was significantly higher than that of 263 
fructose-supplemented rats (1.15-fold). Despite this difference, only the fructose group 264 
exhibited a significant increase in final body weight (by 1.1-fold). Due to the increase in 265 
body weight, organ weights were normalized to femur length, which was not altered by 266 
sugar supplementation. Liver weight was increased only by fructose supplementation 267 
(by 1.4-fold vs control, and 1.3-fold vs glucose-fed rats), whereas adipose tissue weight 268 
was significantly increased in both sugar-supplemented groups (by 5.6-fold in the 269 
glucose group and 5.2-fold in the fructose group). Consistent with the increase in 270 
adiposity, plasma leptin levels and adipose tissue leptin mRNA expression were also 271 
elevated in both experimental groups (Table 2).    272 
  Blood lipid analysis revealed that the cholesterol concentration was not modified 273 
in either glucose- or fructose-supplemented rats (Table 2). However, the levels of 274 
triglycerides were significantly increased in blood taken from fructose-supplemented 275 
rats (by 1.2-fold, Table 2).       276 
  Both sugars induce hepatic lipogenesis but only fructose increases 277 
microsomal triglyceride transfer protein expression 278 
  The hypertriglyceridemia and increased liver weight observed in fructose-279 
supplemented rats prompted us to examine the mRNA/protein expression of 280 
lipogenesis-related enzymes. The mRNA expression of stearoyl-CoA desaturase-1 281 
(scd1) was increased by glucose (3.4-fold) and fructose (4.2-fold) (Figure 1A). 282 
Accordingly, SCD1 protein levels were increased after glucose and fructose 283 
supplementation (by 1.4 and 1.7-fold, respectively), but the increase in the glucose 284 
group did not reach statistical significance (Figure 1B). Although the mRNA expression 285 
of fatty acid synthase (fas) showed a non-significant tendency to increase in both groups 286 
(Figure 1C), FAS protein levels were significantly increased by 2-fold in glucose-287 
supplemented and by 2.4-fold in the fructose-supplemented group (Figure 1D). The 288 
amount of total and phosphorylated acetyl-CoA carboxylase (ACC) was significantly 289 
increased in the liver by both sugars (Figure 1E, F), suggesting that the degree of ACC 290 
activation was not modified. The expression of these lipogenic genes is mainly 291 
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controlled by two transcription factors, sterol response element binding protein-1c 292 
(SREBP-1c) and carbohydrate response element binding protein (ChREBP). Although 293 
the amount of ChREBP in nuclear extracts remained unaffected (Figure 1G), the protein 294 
expression of the mature form of SREBP-1c was significantly increased only in hepatic 295 
nuclear extracts taken from fructose-supplemented rats (Figure 1H).  296 
  As shown in Table 2, only glucose-supplemented animals displayed higher 297 
plasma adiponectin levels than controls (2.6-fold increase), which correlates with 298 
increased mRNA expression of the adiponectin gene in adipose tissue of this group (by 299 
2.6-fold, Table 2). It has been shown that stimulation of adiponectin signalling activates 300 
peroxisome proliferator-activated receptor α (PPARα), a key factor in the transcriptional 301 
control of genes encoding fatty acid β-oxidation enzymes (29). Western blot analysis 302 
revealed that the expression of hepatic PPARα was significantly increased only in the 303 
nuclear extracts from glucose-supplemented rats (by 1.3-fold) (Figure 2A). 304 
Accordingly, the mRNA levels of PPARα target genes, such as liver carnitine 305 
palmitoyl-CoA transferase-I (l-cpt-1a) and acyl-CoA oxidase (aco), were significantly 306 
increased only in the liver of glucose-supplemented animals (Figure 2B, C). When we 307 
determined L-CPT-1A protein levels, we found no significant difference between the 308 
glucose-supplemented and the control group. However, the protein level of L-CPT-1A 309 
was significantly reduced in liver samples taken from fructose-supplemented rats (by 310 
0.5-fold, Figure 2D). Since the amount of plasma triglycerides not only depends on the 311 
balance between the synthesis and catabolism of fatty acids in the liver, but also on the 312 
export of triglycerides from hepatocytes, we also determined the protein expression of 313 
microsomal triglyceride transfer protein (MTP). This protein is essential for the 314 
assembly and secretion of very-low density lipoproteins (VLDL) by the liver. As shown 315 
in Figure 2E, MTP protein expression was increased only in fructose-supplemented rats.   316 
  Supplementation with fructose and glucose impairs insulin signalling in 317 
aorta and liver  318 
  Plasma glucose concentrations were not altered after simple sugar 319 
supplementation (Table 2). On the other hand, fructose increased plasma insulin 320 
concentration (by 2.4-fold) and the glucose-supplemented group showed a tendency 321 
(P=0.07) to higher plasma insulin level. Thus, the insulin sensitivity index (ISI) was 322 
significantly reduced in both glucose- and fructose-supplemented rats (Table 2), 323 
suggesting that insulin signalling could be impaired in these groups. Therefore, we 324 
analyzed the expression of insulin receptor substrate (IRS)-1 and IRS-2, the main 325 
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insulin signal transducers in the liver and in aortic tissue. Our results show that the 326 
protein expression of hepatic IRS-1 was not altered by sugar supplementation (Figure 327 
3A), but IRS-2 expression was significantly reduced in both groups (by 0.5-fold in 328 
glucose-supplemented and by 0.4-fold in fructose-supplemented animals, Figure 3B). 329 
On the other hand, both IRS-1 and IRS-2 protein levels were reduced in aortic tissue 330 
from fructose- and glucose-supplemented rats (Figure 3C, D). We also determined the 331 
expression of V-akt murine thymoma viral oncogene homolog-2 (Akt), one of the main 332 
transducers of insulin signalling downstream of IRS in both tissues. The amount of 333 
phosphorylated Akt (p-Akt) was significantly reduced only in the livers of fructose-334 
supplemented rats in comparison with the control group, whereas total Akt protein 335 
remained unaffected by both sugars (Figure 3E). Similarly, in aortic tissues the 336 
expression of p-Akt was significantly reduced only in fructose-fed animals and total Akt 337 
expression was not significantly modified by sugar supplementation (Figure 3F). 338 
  Supplementation with glucose and fructose alters relaxation responses of 339 
aortic rings to a NO donor 340 
  Relaxation to ACh was used to examine the effect of simple sugars on the 341 
receptor-mediated endothelium-dependent release of NO. No significant differences in 342 
responses to ACh (10-8-10-5 M) occurred between aortic rings from the control, glucose- 343 
and fructose-supplemented groups (Figure 4A). Both the sensitivity of aortic rings to 344 
ACh as assessed by -log[EC50] (pD2) and the Emax to ACh were similar in all groups 345 
(Figure 4A, Table 3). Similar to the findings for ACh, the sensitivity and Emax to BK, 346 
another receptor-mediated endothelium-dependent vasodilator agent were not affected 347 
by sugar supplementation (Figure 4B, Table 3). However, there was a significant 348 
rightward shift of BK response curve in aortic rings from fructose-supplemented rats 349 
relative to control animals (Figure 4B). 350 
  Aortic relaxation responses to a NO donor were also investigated by performing 351 
concentration response curves to SNP (10-9-10-5 M). Although the Emax to SNP was 352 
similar in all groups (Table 3), supplementation with glucose significantly augmented 353 
the responsiveness of aortic rings to SNP. On the other hand, fructose supplementation 354 
significantly attenuated the sensitivity of aortic rings to SNP (Figure 4C, Table 3). 355 
  Glucose (but not fructose) supplementation reduces the contractile response 356 
of aortic rings  357 
  Eight week fructose supplementation did not affect vasoconstrictor responses of 358 
rat aorta to PE, as shown in Figure 5A and Table 3. However, PE-induced maximal 359 
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contractions were significantly reduced in aortic rings from glucose-supplemented rats 360 
compared with controls (Figure 5A, Table 3). Despite PE contractile responses were 361 
affected by glucose supplementation, the mRNA expression of α1-adrenergic receptors 362 
was unchanged (Table 5). To study the possible role of basal NO, PE response curves 363 
were performed in aortic rings before and after pre-treatment with the NO synthase 364 
inhibitor L-NAME (200 μM, 20 min) in the presence of indomethacin (10 μM). The 365 
difference in the contractile level to PE after addition of L-NAME would indicate the 366 
extent of endothelial NO release (13, 20). Incubation of the aortic rings with L-NAME 367 
resulted in a significant increase of the contractile responses to PE in all groups (Figure 368 
5C-E). However, the ΔAUC, defined as difference in the area under the curve between 369 
PE concentration response curve before and after L-NAME were only higher in aortae 370 
of the rats supplemented with glucose compared to the control group (Table 4). 371 
  To investigate a mechanism by which NO release might have been increased in 372 
glucose-supplemented rats, endothelial NO synthase (eNOS) activation by 373 
phosphorylation was investigated. As shown in Figure 6A, the phosphorylation of 374 
eNOS at Ser1177 was increased in aortic tissue from glucose- but not fructose-375 
supplemented rats, whereas in the expression of total eNOS showed no significant 376 
difference between the simple sugar supplemented groups and the control group.  377 
  On the other hand, protein levels of inducible NOS (iNOS) in aorta were 378 
significantly increased only in the fructose-supplemented animals (by 1.8-fold) (Figure 379 
6B). 380 
In vitro adiponectin (but not glucose or fructose) treatment increases NO 381 
level in EA.hy926 382 
It is well known that adiponectin stimulates the synthesis of NO in endothelial 383 
cells. Thus, the increase in adiponectin levels observed in glucose-supplemented rats 384 
could be responsible for the elevated basal NO in this group. To test this hypothesis, we 385 
determined the effects of adiponectin or high glucose or fructose on NO level in 386 
endothelial EA.hy926 cells. As shown in Figure 7, incubation of Eahy926 cells with 25 387 
mM glucose or fructose for 30 min did not alter cellular NO production, whereas 388 
incubation with 5 and 15 µg/ml adiponectin, dose dependently (and significantly for the 389 
highest concentration) increased NO levels in the cell culture supernatant. 390 
  Differential effects of fructose and glucose supplementation on intracellular 391 
pathways related to aortic relaxation  392 
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  To study the molecular mechanisms that could explain the differences in the 393 
responses of aortic rings from rats supplemented with glucose or fructose, the 394 
expression of several molecular mediators of vascular relaxation were examined. The 395 
NO-dependent relaxation is mediated by cGMP signalling which leads to the 396 
stimulation of a specific cGMP-dependent protein kinase (PKG), resulting in the 397 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in Ser239 (44). Our 398 
results show that the mRNA expression of soluble guanylate cyclase (gcsa1) in aortae 399 
from fructose-supplemented rats was reduced by 0.8-fold compared to controls (Figure 400 
8A). Neither the mRNA levels of the phosphodiesterase that hydrolyses cGMP (pde5) 401 
(Figure 8A), nor the protein expression of protein kinase G (PKG) (Figure 8B) were 402 
significantly modified by sugar supplementation. However, phosphorylation of VASP 403 
in Ser239 was reduced in both sugar-supplemented groups vs control (Figure 8C), and 404 
the amount of total VASP showed also a reduction, which was significant only in 405 
fructose-supplemented rats (Figure 8D). 406 
  The NO-independent vasodilatory pathway in large conduit arteries is mainly 407 
controlled by cAMP levels resulting in the phosphorylation of VASP in Ser157 (44). 408 
Aortic tissue adenylyl cyclase (AC6) mRNA levels and phosphorylation of protein 409 
kinase A (PKAc) in Thr197 were not significantly modified by sugar supplementation 410 
compared to control rats, although fructose-supplemented rats showed reduced values 411 
compared to the glucose group (Figure 8A, F). Fructose supplementation significantly 412 
increased the mRNA and protein expression (by 1.9-fold and 1.5-fold, respectively) of 413 
phosphodiesterase 4 (PDE4), which specifically catalyzes the hydrolysis of cAMP 414 
(Figure 8A, G). Thus, the combined reduction of total VASP and the putative decrease 415 
of cAMP levels may explain the significant reduction of VASP Ser157 phosphorylation 416 
(by 1.46-fold) which was observed only in fructose-supplemented rats (Figure 8E).  417 
  Finally, in order to rapidly identify possible changes in other pathways involved 418 
in the vascular effects of simple sugars, we measured the mRNA level of a broad range 419 
of genes associated with vascular function. As shown in Table 5, the mRNA expression 420 
of genes and enzymes such as angiotensin II and BK receptors, cyclooxygenases, 421 
prostacyclin synthase or thromboxane synthase, which have been reported to be 422 
involved in aortic reactivity, remained unaffected by sugar supplementation. Although 423 
we are aware that mRNA expression and protein abundance are not always well 424 
correlated, the lack of effect of sugar supplementation on the mRNAs analyzed 425 
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discouraged us from further studying the involvement of these pathways on the 426 
observed vascular effects. 427 
 428 
  Discussion  429 
  The adverse effects of simple sugar consumption on metabolic function are well 430 
documented in human and animal studies (3, 49, 51), and there are also reports on the 431 
effects of diets supplemented with fructose or high fructose corn syrup on vascular 432 
reactivity in rodents (2, 5, 16, 31, 38). Most of these studies were performed on males, 433 
but there is increasing awareness to include females in research studies. To our 434 
knowledge we are the first to compare the effects of simple sugars (glucose or fructose) 435 
consumption on female rat metabolic factors and aortic function. Here, we identify 436 
some key molecular targets responsible for metabolic and vascular disturbances induced 437 
by simple sugar supplementation in liquid form to female rats. We also provide 438 
evidences that these effects are not merely a direct result of the amount of ingested 439 
calories.  440 
  We previously reported that the ingestion of liquid fructose elicits an incomplete 441 
compensatory reduction of solid food consumption in rats, leading to an increase in total 442 
caloric intake (7, 41–43, 54, 55). Our current data show that when rats are supplemented 443 
with a glucose solution, the compensatory response is even worse compared with 444 
fructose supplementation, as liquid intake is higher and comparatively solid food 445 
consumption is reduced to a lesser extent. As a result, the total caloric intake is higher in 446 
rats receiving glucose than in rats with fructose supplementation (Table 2). It has been 447 
suggested that if simple sugars cause any adverse effects on health, these effects are 448 
exclusively due to the calories that the sugars provide (26). According to this 449 
hypothesis, the metabolic and vascular alterations in the present study should have been 450 
equal or more intense in glucose-supplemented rats. On the contrary, our results show 451 
that compared with the fructose group, rats supplemented with liquid glucose exhibit 452 
less adverse metabolic and vascular effects. Analysis of the results shown in Table 2 453 
and Figure 3 indicates that both sugars impair insulin signalling in the liver and aortic 454 
tissue, but the effect is far more intense in fructose- than in glucose-supplemented rats. 455 
Although hepatic and aortic IRS-1/2 were reduced to a similar extent by glucose and 456 
fructose, p-Akt was significantly decreased in the liver and aorta of fructose-457 
supplemented animals only. This is in accordance with our previous results showing an 458 
abnormal glucose tolerance test and reduced p-Akt in female rats supplemented with 459 
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10% liquid fructose, but not glucose, for 2 months (6). In the current study, insulin 460 
resistance is observed not only in the liver but also in aortic tissues of fructose-461 
supplemented animals, suggesting a common origin for both metabolic and vascular 462 
dysfunction.  463 
  Moreover, our data shows that the hypertriglyceridemia appears only in fructose-464 
supplemented rats. This observation cannot be explained solely by increased hepatic 465 
lipogenesis, as both sugars induced the expression of major lipogenic genes. However, 466 
fructose supplementation induced a more prominent effect (Figure 1). Hepatic 467 
lipogenesis is controlled by two transcription factors, SREBP-1c and ChREBP (57). As 468 
ChREBP is activated by phosphorylated intermediates derived from the direct 469 
metabolism of dietary carbohydrates (1), the 12-h fasting period in our study explains 470 
the lack of activation of this transcription factor (Figure 1G). On the contrary, activation 471 
of SREBP-1c by carbohydrates is not a direct effect but it is mediated by an increase in 472 
plasma insulin levels (57), a mechanism that is maintained in insulin resistance states 473 
(24). In the present study, plasma insulin level was markedly elevated only in fructose-474 
supplemented animals (Table 2), driving the increased expression of SREBP-1c in 475 
hepatic nuclear extracts from this group (Figure 1H). 476 
  Regarding lipid catabolism, fructose supplementation did not affect hepatic 477 
PPARα nuclear content or the mRNA expression of l-cpt-1a, a PPARα target gene. 478 
However, when we determined the protein expression of L-CPT-1A, we observed a 479 
significant decrease in the liver of the fructose-supplemented rats (Figure 2D). L-CPT-480 
1A catalyzes the rate-limiting step of the hepatic mitochondrial β-oxidation of fatty 481 
acids, suggesting that this process may be inhibited in the liver by fructose 482 
supplementation. On the contrary, fructose increased the hepatic expression of MTP, a 483 
protein which is essential for the assembly of triglycerides into VLDL and for the 484 
secretion of these lipoproteins (17). This effect had been already reported in fructose-485 
fed hamsters, and was correlated to hepatic insulin resistance (11, 50). Taking these 486 
results together, the hypertriglyceridemia observed in the fructose-supplemented rats 487 
may arise from the combined effects of increased lipogenesis, reduced fatty acid 488 
catabolism and enhanced triglyceride export from liver to plasma in the form of VLDL 489 
through MTP induction.  490 
  On the other hand, plasma adiponectin level is increased in glucose-491 
supplemented rats, which correlates with increased mRNA expression of adiponectin in 492 
adipose tissue of this group (Table 2). Although the mechanism responsible for this 493 
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inductive effect is unclear, our results suggest that the overexpression of hepatic PPARα 494 
in this group may be due to the elevated level of adiponectin. This theory is supported 495 
by other reports showing that adiponectin up-regulates PPARα expression (58). It 496 
should be noted that despite PPARα induction and elevated l-cpt-1a mRNA in the 497 
glucose-supplemented group, we did not observe increased hepatic CPT-1A protein 498 
expression, suggesting that fatty acid oxidation is not induced by glucose 499 
supplementation. Overall, our results on the decreased L-CPT-1A protein levels in 500 
fructose-supplemented rats suggest that simple sugars might affect L-CPT-1A protein 501 
stability, causing a reduction in its hepatic content. However, this effect is counteracted 502 
in glucose-supplemented rats, possibly via the control of its expression by increased 503 
PPARα. 504 
  It has been shown that adiponectin stimulates NO production in vascular 505 
endothelial cells (12), and therefore the enhanced basal NO in aortae of glucose- 506 
supplemented rats (Table 4) may result from an increased adiponectin in this group. In 507 
the current study, we assessed the in vitro effects of adiponectin or high glucose or 508 
fructose on NO level by measuring NO metabolites. Treatment of EA.hy926 with 509 
adiponectin but not high glucose or fructose caused a signiﬁcant increased in NO level 510 
in these cells (Figure 7). These results exclude a direct effect of glucose on NO 511 
production and suggest that elevated adiponectin is the possible cause of increased NO 512 
in aortae of glucose-supplemented rats. Moreover, it has been reported that adiponectin 513 
stimulates the synthesis of NO in endothelial cells by phosphorylation of eNOS at 514 
Ser1177 (12, 15), and our results show that eNOS phosphorylation at this position is 515 
increased in aortic tissues from glucose-supplemented rats (Figure 6A). Taken together, 516 
these results suggest that the increase in basal NO after glucose supplementation could 517 
be mainly attributed to the hyperadiponectinaemia observed in this group. 518 
  Elevated basal NO in aortae from glucose-supplemented rats may also, in part, 519 
explain decreased vasoconstrictor response to PE in this group (Figure 5B). In addition, 520 
the fact that the SNP-induced relaxation was increased in the glucose-supplemented 521 
group suggests that the increased sensitivity of intact aorta to NO may also contribute to 522 
the decreased PE contractile responsiveness. It is important to note that glucose 523 
supplementation enhanced aortic responses to SNP despite a decrease in 524 
phosphorylation of VASP at Ser239 and preserved PKG expression, suggesting that 525 
VASP phosphorylation or upstream cGMP-dependent phosphorylation of VASP is not a 526 
mechanism for the increased relaxation response to SNP. Along similar lines, Aszódi et 527 
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al. observed an intact relaxation after exposure to cGMP and cAMP in aortic rings of 528 
VASP-null mice (4). Furthermore, Yousif et al. (60) reported that SNP induces cGMP-529 
independent vasodilator responses in the perfused rabbit ovarian vascular bed.  Unlike 530 
the glucose-supplemented group, our data show that SNP-induced relaxation is 531 
significantly reduced in aortic rings of the fructose-supplemented rats. Assessments of 532 
vasodilatory responses in the presence of a soluble guanylate cyclase inhibitor or a PKG 533 
inhibitor/activator could help to determine how fructose and glucose differentially 534 
influence the NO/cGMP/PKG relaxation pathways.  535 
  EDV is used as a reproducible parameter to investigate endothelial function 536 
under various pathological conditions. In the present study, we showed a preserved 537 
EDV of the aorta in the sugar-supplemented rats despite the altered relaxation responses 538 
to SNP. Accordingly, Mourmoura et al. (33) reported that the EDV of coronary arteries 539 
was fully maintained while the response to a NO donor was even enhanced in type 2 540 
diabetic rats. Both impairment (16, 31, 38) or no change  (23, 36) of EDV in vessels 541 
from fructose-supplemented rats have been reported. The varied vasodilatory responses 542 
after sugar supplementation may be attributed to differences in the type of the agents 543 
used, animal’s sex and strain, vascular beds, and duration of sugar supplementation.  544 
  NO has been generally considered as the principal mediator of EDV in normal 545 
state in large arteries, and impaired EDV is often associated with reduced bioavailability 546 
of NO. However prostaglandin I2 (PGI2), and endothelium-derived hyperpolarizing 547 
factor (EDHF) may also be important regulators of vascular tone and reactivity in 548 
diabetes. There is an established negative regulatory effect of NO on EDHF synthesis 549 
(8). On the other hand, an augmented EDHF response was shown to compensate for the 550 
loss of NO-mediated vasorelaxation in arteries in diabetic rats (46). In agreement with 551 
those studies that demonstrate compensatory interactions between pathways, the 552 
preserved ACh response (regardless of altered SNP responses) suggest that other 553 
molecules besides NO (e.g. EDHF or PGI2) may be involved in ACh relaxation. The 554 
fact that AC6 mRNA and phosphorylated PKA protein levels were significantly reduced 555 
in aorta taken from fructose rats (Figure 8A, F) suggests that the preserved ACh 556 
responses in the arteries of this group is likely due to the elevated EDHF (rather than 557 
increased PGI2). Furthermore, we demonstrated that fructose- but not glucose-558 
supplementation enhances PDE4 mRNA and protein expression (Figure 8A, G). The 559 
elevated PDE4 expression and subsequent reduction in cAMP levels may specifically 560 
hinder phosphorylation of VASP at Ser157 (Figure 8E). This effect combined with 561 
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reduced VASP expression (Fig 8D) possibly leads to an impairment of NO-independent 562 
relaxation in aortae of fructose-supplemented rats.  563 
  Another mechanism that could account for the difference between the response 564 
to ACh and SNP could be oxidative stress. Reactive oxygen species (ROS), particularly 565 
superoxide anions, inactivate NO which could lead to a reduction of SNP potency. In 566 
order to examine this possibility, we measured the mRNA expression of the catalytic 567 
subunits of NADPH oxidase Nox1 and Nox4, major source of ROS in vascular cells 568 
(19). However, we did not see significant differences in the mRNA expression for Nox1 569 
and Nox4 in the aorta of experimental animals (Table 5).  570 
  It has been shown that under metabolic stress conditions iNOS is able to produce 571 
an abnormal amount of NO leading to ROS production and decreased bioavailability of 572 
NO. Although we did not measure ROS production and NO bioavailability, we 573 
observed a significant induction of iNOS protein expression in aortic tissues from 574 
fructose-supplemented rats (Figure 6B), which could in part lead to vascular 575 
dysfunction in this group (35). Vascular dysfunction in metabolic syndrome may also be 576 
associated with increased vasoconstrictor sensitivity (47). Here, however, we showed 577 
that fructose supplementation did not affect vasoconstrictor responses to PE. Along 578 
similar lines, no differences were reported in the vasoconstrictor responses to PE in 579 
mesenteric arteries (36) or aortic rings (23) from fructose-fed rats.    580 
  In conclusion, we have shown that dietary supplementation with liquid glucose 581 
or fructose causes metabolic and vascular alterations in female rats.  Despite higher 582 
caloric intake in glucose-supplemented rats, fructose caused worse metabolic and 583 
vascular responses. This may be due to the elevated adiponectin level and the 584 
subsequent enhancement of PPARα and eNOS phosphorylation in glucose-585 
supplemented rats, a mechanism which is absent in the fructose group. Clearly, 586 
additional studies will be needed to document the direction and magnitude of these 587 
interactions in sugar-supplemented rats along with the relative importance of elevated 588 
adiponectin level to metabolic and vascular function in the glucose-supplemented rats.  589 
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 811 
Figure Legends 812 
Figure 1. Supplementation with glucose and fructose induces hepatic lipogenesis. 813 
mRNA levels of scd1 (A) and fas (C) in the liver from control, glucose- and fructose-814 
supplemented rats. Bars represent the mean±SEM of values obtained from n=8 animals. 815 
Protein levels of SCD1 (B), FAS (D), p-ACC (E), total ACC (F), ChREBP (G) and 816 
mature SREBP-1 (F) in liver samples from control, glucose- and fructose-supplemented 817 
rats. Each bar represents the mean±SEM of values obtained from n=5 animals. To show 818 
representative bands corresponding to 3 different rats per treatment group, images from 819 
different parts of the same gel have been juxtaposed, which is indicated by white 820 
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dividing lines in the figure.; *P <0.05, **P <0.01 and ***P <0.001 versus control. One-821 
way ANOVA followed by Bonferroni’s post hoc test. 822 
 823 
Figure 2. Differential effects of glucose and fructose on PPARα, PPARα target 824 
genes and MTP. (A) Protein levels of PPARα (A), L-CPT-1A (D) and MTP (E) in 825 
hepatic samples from control, glucose- and fructose-supplemented rats. Each bar 826 
represents the mean±SEM of values obtained from n=5 animals. To show representative 827 
bands corresponding to 3 different rats per treatment group, images from different parts 828 
of the same gel have been juxtaposed, which is indicated by white dividing lines in the 829 
figure. mRNA levels of l-cpt-1a (B) and aco (C) in hepatic samples from control, 830 
glucose- and fructose-supplemented rats. Each bar represents the mean±SEM of values 831 
obtained from n=8 animals; *P <0.05 and **P <0.01 versus control; ##P <0.01 versus 832 
glucose. One-way ANOVA followed by Bonferroni’s post hoc test. 833 
 834 
Figure 3. Effects of glucose and fructose supplementation on the expression of 835 
proteins involved in insulin signalling in liver and aortic tissues. Protein levels of 836 
hepatic IRS-1 (A), and IRS-2 (B), aortic IRS-1 (C) and IRS-2 (D), and hepatic (E) and 837 
aortic (FD) phosphorylated and total Akt in samples from control, glucose- and 838 
fructose-supplemented rats. Each bar represents the mean±SEM of values obtained from 839 
n=5 animals. To show representative bands corresponding to 3 different rats per 840 
treatment group, images from different parts of the same gel have been juxtaposed, 841 
which is indicated by white dividing lines in the figure. *P <0.05, **P <0.01 and ***P 842 
<0.001 versus control. One-way ANOVA followed by Bonferroni’s post hoc test. 843 
 844 
Figure 4. Effects of supplementation with glucose and fructose on the responses of 845 
aortic rings to relaxation agents. Relaxation responses to cumulative concentrations of 846 
(A) acetylcholine (ACh), (B) bradykinin (BK) and (C) sodium nitroprusside (SNP) in 847 
intact aortic rings from female rats after 2 months of supplementation with 20% w/v 848 
liquid fructose or glucose. Aortic rings were pre-contracted with phenylephrine (2 µM) 849 
(A, B) or U46619 (100 nM) (C). Data are expressed as mean±SEM of values obtained 850 
from n=5-8 animals; *P <0.05 and ***P <0.001 versus control, analyzed using two-way 851 
ANOVA followed by Bonferroni’s post hoc test. 852 
 853 
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Figure 5. Supplementation with glucose reduces the contractile responses of aortic 854 
rings. (A) Contractile responses to cumulative concentrations of phenylephrine (PE) in 855 
intact aortic rings from female rats after 2 months of supplementation with 20% w/v 856 
liquid fructose or glucose. (B-D) Contraction to PE was measured in aortae from 857 
control, glucose- and fructose-supplemented rats before and after incubation with Nω-858 
Nitro-L-arginine methylester (L-NAME, 200 μM). Responses were performed in the 859 
presence of indomethacin (10 μM). Data are expressed as mean±SEM of vàlues 860 
obtained from n=7-8 animals; *P < 0.05 and ***P <0.001 versus control condition 861 
(control rats in A, before L-NAME in B-D), analyzed using two-way ANOVA followed 862 
by Bonferroni’s post hoc test.  863 
 864 
Figure 6. Supplementation with glucose enhances eNOS phosphorylation and 865 
supplementation with fructose increases iNOS expression in aortic tissue. Western 866 
blots of phosphorylated and total eNOS (A) and iNOS (B) in aortic samples from 867 
control, glucose- and fructose-supplemented rats. Each bar represents the mean±SEM of 868 
values obtained from n=5 animals. To show representative bands corresponding to 3 869 
different rats per treatment group, images from different parts of the same gel have been 870 
juxtaposed, which is indicated by white dividing lines in the figure. *P <0.05 versus 871 
control, ##P <0.01 versus glucose. One-way ANOVA followed by Bonferroni’s post hoc 872 
test. 873 
 874 
Figure 7. In vitro adiponectin (but not glucose or fructose) increases NO level in 875 
EA.hy926 cells. Levels of nitrate and nitrite in EA.hy926 medium after incubation with 876 
vehicle (CT), adiponectin (APN, 5 and 15 μg/ml), 25 mM glucose, 25 mM fructose, 25 877 
mM mannitol (MAN) and the NO donor SNAP (100 µM). Each bar represents the 878 
mean±SEM of five to six different assays performed in duplicate. ***P <0.001 and 879 
****P <0.0001 versus control. One-way ANOVA followed by Bonferroni’s post hoc 880 
test. 881 
 882 
Figure 8. Differential effects of fructose and glucose supplementation on 883 
intracellular pathways related to aortic relaxation.  (A) mRNA levels of ac6, gcsa1 , 884 
pde4dand pde5 in aortic tissue samples from control, glucose- and fructose-885 
supplemented rats. Each bar represents the mean±SEM of values obtained from n=8 886 
animals. Protein levels of PKG (B), VASP phosphorylated in Ser239 (C), total VASP 887 
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(D), and VASP phosphorylated in Ser157 (E), phosphorylated PKAc (F) and PDE4 (G) 888 
in aortic samples from control, glucose- and fructose-supplemented rats. Each bar 889 
represents the mean±SEM of values obtained from n=5 animals. To show representative 890 
bands corresponding to 3 different rats per treatment group, images from different parts 891 
of the same gel have been juxtaposed, which is indicated by white dividing lines in the 892 
figure. *P <0.05 and ***P <0.001 versus control, ##P <0.01 versus glucose. One-way 893 
ANOVA followed by Bonferroni’s post hoc test. 894 
 895 
 896 
 897 
Table 1: Primers used for RT-PCR 
Gen GenBankTM nº Primer sequences  PCR product 
ac6 NM_001270785.1 Forward: 5'-FCTTTGCCACCAGTTCTCTGC-3' 107 bp Reverse: 5'-GCCTTGGCTAATTAAGCGCC-3' 
ace NM_012544.1 Forward: 5'-GAGCCATCCTTCCCTTTTTC-3' 154 bp Reverse: 5'-GGCTGCAGCTCCTGGTATAG-3' 
aco NM_017340.2 Forward: 5'-GTGAGGCGCCAGTCTGAAA-3' 70 bp Reverse: 5'-ACTGCTGGGTTTGAAAATCCA-3' 
actb NM_031144.3 Forward: 5'-CTAAGGCCAACCGTGAAAAG-3' 55 bp Reverse: 5'-GGGGTGTTGAAGGTCTCAAA-3' 
adipoq NM_144744.3 Forward: 5'-GAGACGCAGGTGTTCTTG-3' 148 bp Reverse: 5'-CCTACGCTGAATGCTGAG-3' 
adra1b NM_016991.2 Forward: 5'-AGCGGTAGATGTCCTGTGCT-3' 164 bp Reverse: 5'-AGATGACCGTGGACAAGACC-3' 
aldob NM_012496.2 Forward: 5'-ACAGCCTCCTACACCTACT-3' 198 bp Reverse: 5'-GCTCATACTCGCACTTCA-3' 
agtr1a NM_030985.4 Forward: 5'-CACAGTGTGCGCGTTTCATT-3' 63 bp Reverse: 5'-GTAAGGCCCAGCCCTATGG-3' 
agtr2 NM_012494.3 Forward: 5'-TTGTGTTGGCATTCATCATTTG-3' 76 bp Reverse: 5'-ATACCCATCCAGGTCAGAGCAT-3' 
bdkrb1 NM_030851.1 Forward: 5'-CAGCGCTTAACCATAGCGGAAAT-3' 112 bp Reverse: 5'-CCAGTTGAAACGGTTCCCGATGTT-3' 
bdkrb2 NM_173100.2 Forward: 5'-TTTGTCCTCAGCGTGTTCTG-3' 226 bp Reverse: 5'-TCACAAGCATCAGGAAGCAG-3' 
cox1 NM_017043.4 Forward: 5'-AAGTACTCATGCGCCTGGTACTC-3' 75 bp Reverse: 5'-CATGTGCTGTGTTGTAGGTTGGA-3' 
cox2 NM_017232.3 Forward: 5'-TCGACTTTTCCAGGATGGAAA-3' 77 bp Reverse: 5'-GAGTGTCTTTGACTGTGGGAGGAT-3' 
enos NM_021838.2 Forward: 5'-GTGACCCTCACCGATACAACATAC-3' 73 bp Reverse: 5'-GATGAGGTTGTCCGGGTGTCT-3' 
fas NM_017332             Forward: 5’-GGCTCTATGGGTTGCCTAAGC-3’ 78 bp Reverse: 5’-GGTGGACCCCAAAAAAGGA-3’ 
gcsa1  NM_017090.2 Forward: 5'-CAGTGTGGAGAGCTGGATGTCT-3' 68 bp Reverse: 5'-AATCCCCCTGCCACACAAT-3' 
l-cpt1a NM_031559.2 Forward: 5’-TGCAGAACACGGCAAAATGA-3’ 70 bp Reverse: 5’-CCGACCTGAGAGGACCTTGA-3’ 
leptin NM_013076.3 Forward: 5'-GGTCACCGGTTTGGACTTCA-3' 67 bp Reverse: 5'-GGTCTGGTCCATCTTGGACAA-3' 
nox1 NM_053683.1 Forward: 5'-ATACACATCACCTTTTCATCATCTATATCA-3' 76 bp Reverse: 5'-GTTTGACCCCGGACAATCC-3' 
nox4 NM_053524.1 Forward: 5'-CGCACAGTCCTGGCTTACCT-3' 75 bp Reverse: 5'-GCTTTTGTCCAACAATCTTCTTGTT-3' 
pde4d NM_001113328.1 
Forward: 5'-GCCAGCCTTCGAACTGTAAG-3' 
98 bp Reverse: 5'-ATGGATGGTTGGTTGCACAT-3' 
 
ac: adenylyl cyclase; ace: angiotensin I converting enzyme; aco: acyl-CoA oxidase; actb: actin beta; 
adipoQ: adiponectin, C1Q and collagen domain containing; adra: adrenergic receptor, α; agtr: angiotensin 
II receptor; aldob: aldolase B; bdkr: bradikinin recpetor; cox: cyclooxigenase; eNOS: endothelial nitric 
oxide synthase; fas: fatty acid synthase; gcsa: soluble guanylate cyclase; l-cpt: liver carnitine 
palmitoyltransferase; nox: NADPH oxidase; pde: phosphodiesterase; ptgis: prostaglandin I2 
(prostacyclin) synthase; scd1: stearoyl-CoA desaturase; tbp: TATA box binding protein; tbxas: 
thromboxane synthase. 
pde5 NM_133584.1 Forward: 5'-CCCTTTGGAGACAAAACGAGAG-3'  129 bp Reverse: 5'-AGGACTTTGAGGCAGAGAGC-3' 
ptgis NM_031557.2 Forward: 5'-GCAGGAGAAAGGTCTGCTTGA-3' 75 bp Reverse: 5'-TCCACTCCATACAGGGTCAGGTA-3' 
scd1 NM_139192.2 Forward: 5’- CAGAGCCAGGTGCCACTTTT-3’ 104 bp Reverse: 5’-TGCTAGAGGGTGTACCAAGCTTT-3’ 
tbp NM_001004198.1  Forward: 5’-TGGGATTGTACCACAGCTCCA-3’ 132 bp Reverse: 5’-CTCATGATGACTGCAGCAAACC-3’ 
tbxas NM_012687.1 Forward: 5'-GAGCTCCGAGAGCGATATGG-3' 76 bp Reverse: 5'-CTGGGTCTGAAATGACAATGTACAT-3' 
Table 2. Zoometric parameters, plasma/blood analytes and adipokine mRNA levels in 
adipose tissue of female rats supplemented with 20% w/v liquid fructose or glucose for 
2 months                                                                          
 
 Control  Glucose Fructose 
AUC liquid intake             
(ml/[rat x 2 months]) 
2378 ± 127 4778 ± 185*
 
3577 ± 182*, #
 
AUC solid food intake        
(g/[rat x 2 months]) 
874,8 ± 19,5 
  
302,6 ± 24,4*
 
415,4 ± 21,1*, # 
 
Kcal ingested from solid          
(rat x 2 months) 
2642 ± 59 914 ± 74* 1255 ± 634*, #
 
Kcal ingested from liquid   
(rat x 2 months) 
 
0 3822 ± 148 2862 ± 146 
Total ingested kcal            
 (2 rats x 2 months)a 
2642 ± 59 4736 ± 158* 
 
4116 ± 129*, # 
 
 
Final body weight 239.1 ± 3.9 245.1 ± 5.5 254.9 ± 5.9* 
 
Femur length (cm) 3.32 ± 0.10 3.35 ± 0.05 3.38 ± 0.12 
Adipose tissue weight (g)/femur 
length (cm) 
0.37 ± 0.08 2.06 ± 0.29*
 
1.91 ± 0.38* 
 
Liver weight (g)/femur length 
(cm) 
2.92 ± 0.10 3.16 ± 0.19* 
 
4.00 ± 0.09*, # 
 
Plasma leptin (ng/ml) 2.46 ± 0.08 4.51 ± 0.09*
 
3.89 ± 0.08*, #
 
Adipose tissue leptin mRNA 
levels (a.u) 
100 ± 22 189 ± 28* 193 ± 26* 
Plasma adiponectin (µg/ml) 22.58 ± 2,4 58.42 ± 5,0*
 
26.48 ± 2.5
Adipose tissue AdipoQ mRNA 
levels (a.u) 
100 ± 23 263 ± 48* 140 ± 32 
Plasma insulin (mg/dl) 0.67 ± 0.13 1.24 ±0.24 1.64 ± 0.35*
 
Blood glucose (mg/dl) 101.7 ± 5.1 112.7 ± 5.9 109.7 ± 6.0 
Blood triglycerides (mg/dl) 116.1 ± 3.9 125.7 ± 2.8 144.4 ± 13.1* 
 
ISI 1.23 ± 0.02 0.88 ± 0.03* 0.76 ± 0.02*
Blood cholesterol (mg/dl) 166.0 ± 1.4 166.6 ± 0.9 165.5 ± 0.8 
ISI: Insulin Sensitivity Index, calculated as [2/(blood insulin (nM) x blood glucose (µM) + 1]. 
Values are expressed as mean ± SEM (n= 14 rats/group for plasma / blood analytes and 
zoometric parameters;  n=8 rats/group for mRNA expression). *P<0.05 vs control; # P<0.05 vs 
glucose-supplemented rats. One-way ANOVA test followed by Bonferroni’s post hoc test. 
Table 3. pD2 and Emax or tensionmax to vasodilator and vasoconstrictor agents in the 
aortae from female rats supplemented with 20% w/v liquid fructose or glucose for 2 
months 
  n pD2 E max (%) 
Ach Control 8 6.75 ± 0.15 85.21 ± 2.63 
Glucose 8 6.86 ± 0.10 85.59 ± 2.12 
Fructose 8 6.88 ± 0.15 87.59 ± 2.46 
     
BK Control 5 6.27 ± 0.51 90.51 ± 4.26 
Glucose 6 5.00 ± 0.80 62.48 ± 14.22 
Fructose 5 4.58 ± 0.69 54.38 ± 16.60 
     
SNP Control 8 8.97 ± 0.07 100.23 ± 0.28 
Glucose 8    9.51 ± 0.10* 100.01 ± 0.19 
Fructose 8 8.64 ± 0.14 100.01 ± 0.19 
     
  n pD2 Tension max (g) 
PE Control 7 7.15 ± 0.08 1.60 ± 0.15 
Glucose 8 7.02 ± 0.08 1.10 ± 0.10* 
Fructose 7 7.32 ± 0.10 1.54 ± 0.14 
Data are expressed as mean ± SEM. *P<0.05, one-way ANOVA test followed by 
Bonferroni’s post hoc test. 
 
Table 4. Emax, tensionmax pD2 and ∆AUC to phenylephrine in the aortae from female 
rats supplemented with 20% w/v liquid fructose or glucose for 2 months 
 n Emax (%) Tensionmax (g) pD2 ∆AUC 
Control 7     
  Before L-NAME  91.10±9.19 1.48±0.24 7.05±0.09 - 
  After L-NAME  139.7±4.00** 2.21±0.18* 7.30±0.07 116.90±21.49 
Glucose 8     
  Before L-NAME  92.05±8.15 0.97±0.07 6.98±0.06 - 
  After L-NAME  179.4±16.07*, # 1.86±0.08** 7.20±0.06 197.24±30.78#
Fructose 7     
  Before L-NAME  81.63±5.32 1.26±0.16 7.05±0.05 - 
  After L-NAME  143.6±11.62* 2.16±0.17* 7.38±0.08 158.90±19.75 
Data are expressed as mean ± SEM. * P<0.05 (vs. before L-NAME), paired Student’s t 
test; # P<0.05 (vs. control), one way ANOVA followed by Bonferroni’s post hoc test. 
 
Table 5. mRNA expression of genes related to vascular reactivity in aortic tissue from 
female rats supplemented or not with 20% w/v liquid fructose or glucose for 2 months 
                                                                       
 
 Control  Glucose Fructose 
Cox-1 100±14 132±6 115±11 
Cox-2 100±7 121±29 77±18 
Ptgis 100±9 95±5 89±5 
Tbxas 100±17 85±10 92±6 
Ace 100±12 87±7 78±7 
Agtr1a 100±25 100±6 91±12 
Agtr2 100±34 94±22 85±25 
Aldob 104±25 149±51 140±39 
Adra1a 100±40 194±65 102±14 
Adra1b 100±8 129±22 144±18 
Adra1d 100±8 114±22 113±18 
Bdkrb1 100±39 93±28 102±45 
Bdkrb2 100±19 142±33 118±25 
Nox1 100±38 123±36 102±36 
Nox4 100±3 130±9 124±7 
 Ace: angiotensin I converting enzyme; Adra: adrenergic receptor, α; Agtr: angiotensin 
II receptor; Aldob: aldolase B; Bdkr: bradikinin recpetor; Cox: cyclooxigenase; Nox: 
NADPH oxidase; Ptgis: Prostaglandin I2 (Prostacyclin) Synthase; Tbxas: Thromboxane 
synthase 








